The dementia was caused by Alzheimers disease, dementia with Lewy bodies, frontotemporal dementia, Parkinsons disease with dementia, or vascular dementia. The trial was stopped early for efficacy. Patients treated with pimavanserin had a relapse in 13%, without in 28% (hazard ratio 0.35; 95% CI = 0.17-0.73; p = 0.005). Longer and larger trials are suggested. Controversy
On April 9, 2018, CNN reported that some in the FDA were concerned that Nuplazid was "risky" when it was approved and noted there have been a substantial number of deaths reported by those using the drug. The story further noted that the drug was approved based on a "six-week study of about 200 patients". The FDA began post-market monitoring of the drug to assess the validity of these claims. On September 20, 2018, the FDA stated their review "did not identify any new or unexpected safety findings with Nuplazid, or findings that are inconsistent with the established safety profile currently described in the drug label". Research
Pimavanserin is under development for the treatment of major depressive disorder, schizophrenia, agitation, and psychiatric disorders. As of March 2022, pimavanserin is in phase 3 clinical trials for major depressive disorder and schizophrenia, phase 2 trials for agitation, and phase 1 trials for psychiatric disorders. It was also under development for the treatment of insomnia, drug-induced akathisia, and drug-induced dyskinesia, but development for these indications was discontinued. See also
List of investigational antipsychotics
List of investigational antidepressants
Ketanserin

References
Further reading
McGuire, Donna (May 10, 2017). "New drug can ease Parkinsons psychosis". Chicago Tribune. p. 5 (section 5) – via Newspapers.com.
Choriocarcinoma is a malignant, trophoblastic cancer, usually of the placenta. It is characterized by early hematogenous spread to the lungs. It belongs to the malignant end of the spectrum in gestational trophoblastic disease (GTD). It is also classified as a germ cell tumor and may arise in the testis or ovary. Signs and symptoms
increased quantitative chorionic gonadotropin (the "pregnancy hormone") levels
vaginal bleeding
shortness of breath
hemoptysis (coughing up blood)
chest pain
chest X-ray shows multiple infiltrates of various shapes in both lungs
presents in males as a testicular cancer, sometimes with skin hyperpigmentation (from excess chorionic gonadotropin cross reacting with the alpha MSH receptor), gynecomastia, and weight loss (from excess chorionic gonadotropin cross reacting with the LH, FSH, and TSH receptor) in males
can present with decreased thyroid-stimulating hormone (TSH) due to hyperthyroidism. Cause
Choriocarcinoma of the placenta during pregnancy is preceded by:

hydatidiform mole (50% of cases)
spontaneous abortion (20% of cases)
ectopic pregnancy (2% of cases)
normal term pregnancy (20–30% of cases)
hyperemesis gravidarumRarely, choriocarcinoma occurs in primary locations other than the placenta;  very rarely, it occurs in testicles. Although trophoblastic components are common components of mixed germ cell tumors, pure choriocarcinoma of the adult testis is rare. Pure choriocarcinoma of the testis represents the most aggressive pathologic variant of germ cell tumors in adults, characteristically with early hematogenous and lymphatic metastatic spread. Because of early spread and inherent resistance to anticancer drugs, patients have poor prognosis. Elements of choriocarcinoma in a mixed testicular tumor have no prognostic importance.Choriocarcinomas can also occur in the ovaries and other organs.